PFE stock forecast examines Pfizer’s pipeline recovery and dividend strength. Analyze PFE stock price, earnings, technicals, and valuation for healthcare investors 

Introduction

Pfizer develops and sells prescription medicines worldwide. It focuses on vaccines, cancer treatments, and heart disease drugs through brands like Prevnar and Ibrance. Investors watch PFE stock now as COVID revenues fade but new blockbusters emerge. Healthcare stocks gain from defensive positioning amid market volatility in March 2026.

Latest stock Price & Trend

PFE stock closed at $26.58 on March 13, 2026 per NYSE data, down 1.04% from $26.86. Volume hit 34.2 million shares during the session. Five-day trend declined 3% from $27.46 March 9 highs.

One-month performance sideways down 4% from late February $27.65 levels. Three-month lost 5%, six-month down 12%. Year-to-date through March 16, PFE stock fell 15%. 52-week range $24.49 low to $30.54 high. Bearish trend signals value opportunity for dividend-focused investors.

Technical Analysis

Support firmly holds at $26.50 matching multiple March lows with volume confirmation. Resistance $27.50 caps recent tests around March 5-6. RSI reads 42, neutral territory approaching oversold conditions.

MACD shows bearish bias below zero line but momentum slowing. 50-day moving average $27.20 sits above 200-day $27.80—no death cross yet. Volume spiked on down days then normalized indicating potential stabilization.​

Analyst Ratings & Price Targets

Analysts set average price target $29.50 with highs $35.00, lows $24.00. Recent Cantor Fitzgerald maintains overweight citing oncology pipeline. Consensus “Hold” reflects pipeline uncertainty balanced by 6% dividend yield.​

Moderate sentiment guides investors toward income over growth positioning.

Insider Activity

Executives sold 200,000 shares last quarter at $28 average for diversification. No significant buying reported. Institutional ownership steady at 68%.

Routine transactions signal confidence in dividend continuity.

Valuation Analysis

Trailing P/E 12.5x undervalues pharma peers averaging 18x. Forward P/E 10.2x attractive on EPS recovery. Price-to-sales 2.3x reasonable post-COVID adjustment.

Revenue declined 8% YoY to $58 billion trailing twelve months. Core EPS growth 5% excluding Comirnaty. Free cash flow $8 billion supports $1.68 annual dividend. $151 billion market cap with manageable $70 billion debt.​

PFE stock appears undervalued relative to pipeline potential and yield.

Recent Earnings & Catalysts

Q4 2025 revenue met lowered expectations at $14.6 billion. Adjusted EPS $0.56 beat $0.54 consensus. Oncology sales grew 12% offsetting vaccine declines.

Pipeline catalysts include Seagen integration adding $10 billion ADC revenue by 2028. Weight loss drug danuglipron Phase 3 data expected Q2—stock stable post-earnings.​

Bullish Case

Oncology portfolio grows 15% annually through 2030. Seagen acquisition delivers $3 billion peak sales from Padcev. Dividend aristocrat status compounds 7% yield.

Cost savings target $4 billion annually by 2027.

Bearish Case

COVID portfolio erosion continues 30% annually. Biosimilar competition pressures Ibrance sales. R&D productivity lags peers at 1:10 success ratio.

Patent cliffs hit $17 billion revenue by 2030.

Market Sentiment & Investor Psychology

Short interest 2.1% minimal pressure. Institutions maintain steady 68% ownership. Retail favors dividend safety over growth.

Sentiment neutral with defensive bias.

Short-Term Outlook

$26.50 support likely holds providing retest of $27.50 resistance. RSI stabilization eyes bounce opportunity.

Volume normalization supports range trading next weeks.

Medium to Long-Term Outlook

Diversified portfolio across therapeutic areas reduces single-drug risk. Pharma market grows 6% CAGR. Pfizer’s scale funds $15 billion annual R&D.

Pipeline execution determines multiple expansion. Long-term investors should accumulate below $26, hold for 6% yield plus recovery.

FAQ

Is PFE stock a buy right now?
Buy for income—deep value with pipeline optionality.

What is the price target for PFE stock?
Analyst average $29.50, 11% upside.​

What are major risks for PFE stock?
Pipeline failures, patent losses, R&D spending.

Next PFE earnings date?
Late April 2026, watch oncology growth.

PFE technical analysis summary?
Oversold bounce potential, downtrend intact.

Suggestion

Compare with Opendoor

See our pharma sector valuation breakdown

Read our dividend stock forecast guide

Conclusion

Buy PFE stock. Compelling dividend yield and undervaluation offset pipeline risks—core defensive holding.

Disclaimer: This article is for informational purposes only and not financial advice.